Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 1051 to 1060 of 1349 total matches.

TNF Inhibitors for Crohn's Disease: When, Which, and for How Long

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013  (Issue 1432)
) – are approved by the FDA for treatment of moderately to severely active Crohn’s disease in adults who have had ...
Three tumor necrosis factor (TNF) inhibitors – infliximab (Remicade), adalimumab (Humira), and certolizumab pegol (Cimzia) – are approved by the FDA for treatment of moderately to severely active Crohn’s disease in adults who have had an inadequate response to conventional therapy. Infliximab is also FDA-approved for the same indication in children ≥6 years old and for treatment of fistulas in adults. All 3 TNF inhibitors have been shown to reduce the signs and symptoms of Crohn's disease in clinical trials. They have been associated with adverse effects such as...
Med Lett Drugs Ther. 2013 Dec 23;55(1432):102-3 |  Show IntroductionHide Introduction

Extended-Release Oxycodone and Acetaminophen (Xartemis XR)

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014  (Issue 1447)
the active ingredients at a steady rate over an extended period. Oxycodone plasma concentrations Extended ...
The FDA has approved a fixed-dose extended-release formulation of oxycodone and acetaminophen (Xartemis XR – Mallinckrodt) for oral treatment of acute pain severe enough to require an opioid. Oxycodone is available in the US as a single entity in oral immediate-release (Oxecta, and others) and extendedrelease (OxyContin) formulations. Immediate-release oxycodone is also available in combination with aspirin (Percodan, and others), acetaminophen (Percocet, and others), or ibuprofen (see Table 1).
Med Lett Drugs Ther. 2014 Jul 21;56(1447):59-61 |  Show IntroductionHide Introduction

Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea

   
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016  (Issue 1485)
and other drugs that reduce GI motility, such as anticholinergics or systemically active opioids, could result ...
The FDA has approved eluxadoline (Viberzi – Actavis), a mu-opioid receptor agonist and delta-opioid receptor antagonist, for oral treatment of adults with irritable bowel syndrome with diarrhea (IBS-D).
Med Lett Drugs Ther. 2016 Jan 4;58(1485):4-5 |  Show IntroductionHide Introduction

A New Abuse-Deterrent Opioid - Xtampza ER

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016  (Issue 1497)
). Patients treated with the active drug had significantly lower pain scores from week 2-12 than those who ...
The FDA has approved Xtampza ER (Collegium), a new extended-release, abuse-deterrent capsule formulation of oxycodone, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Med Lett Drugs Ther. 2016 Jun 20;58(1497):77-8 |  Show IntroductionHide Introduction

Two New Amphetamines for ADHD

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016  (Issue 1497)
/day) of the new suspension over 5 weeks, followed by 1 week of treatment with either the active drug ...
Two new extended-release amphetamine products have been approved by the FDA for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old: Adzenys XR-ODT (Neos Therapeutics), an orally distintegrating tablet, and Dyanavel XR (Tris Pharma), an oral suspension.
Med Lett Drugs Ther. 2016 Jun 20;58(1497):80-1 |  Show IntroductionHide Introduction

Abuse-Deterrent Opioids

   
The Medical Letter on Drugs and Therapeutics • Jun 05, 2017  (Issue 1522)
manipulation should then be conducted. Based on these results, a randomized, doubleblind, placebo- and active ...
Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Since our last article on this subject, several new abuse-deterrent opioid formulations have been approved by the FDA, including an oxycodone tablet formulation (Roxybond – Inspirion) that is the first immediate-release opioid product FDA-approved to include claims of abuse deterrence in its labeling. No opioid formulation prevents consumption of a large number of intact dosage units, the most common method of...
Med Lett Drugs Ther. 2017 Jun 5;59(1522):95-6 |  Show IntroductionHide Introduction

Hydrogen Peroxide 40% (Eskata) for Seborrheic Keratoses

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018  (Issue 1556)
, all 4 lesions were graded clear in 4% and 8% of patients treated with the active drug (see Table 1 ...
The FDA has approved hydrogen peroxide 40% topical solution (Eskata – Aclaris Therapeutics) for treatment of raised seborrheic keratoses (SKs) in adults. It is the first drug to be approved for this indication. (Hydrogen peroxide is available over the counter for topical use as a 3% solution.)
Med Lett Drugs Ther. 2018 Sep 24;60(1556):157-8 |  Show IntroductionHide Introduction

Brexanolone (Zulresso) for Postpartum Depression

   
The Medical Letter on Drugs and Therapeutics • May 06, 2019  (Issue 1571)
for treatment of refractory PPD.1 PHARMACOLOGY — Brexanolone positively modulates neuronal activation ...
The FDA has approved the GABAA receptor modulator brexanolone (Zulresso – Sage Therapeutics) for IV treatment of postpartum depression (PPD). Brexanolone is the first drug to be approved by the FDA for this indication.
Med Lett Drugs Ther. 2019 May 6;61(1571):68-70 |  Show IntroductionHide Introduction

Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia

   
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019  (Issue 1581)
is readily absorbed through the nasal mucosa. It activates glucagon receptors in the liver, stimulating ...
The FDA has approved glucagon nasal powder (Baqsimi – Lilly) for treatment of severe hypoglycemia in patients ≥4 years old with diabetes. Baqsimi is the first noninjectable glucagon formulation to become available in the US. Injectable glucagon emergency kits (GlucaGen Hypokit, and generic) have been available for years, but they require reconstitution of the lyophilized powder by the caregiver immediately before injection. An injectable glucagon formulation that does not require reconstitution was recently approved by the FDA (Gvoke) and is expected to become available...
Med Lett Drugs Ther. 2019 Sep 23;61(1581):148-9 |  Show IntroductionHide Introduction

COVID-19 Updates

   
The Medical Letter on Drugs and Therapeutics • Apr 18, 2022  (Issue 1648)
to be effective for treatment of COVID-19 caused by BA.2; it has significantly less neutralizing activity ...
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use as a second booster dose ≥4 months after a first booster dose in adults ≥50 years old and in persons aged ≥12 years (Pfizer) or ≥18 years (Moderna) who have undergone solid organ transplantation or have a condition that compromises the immune system to a similar extent.
Med Lett Drugs Ther. 2022 Apr 18;64(1648):63-4 |  Show IntroductionHide Introduction